Clinics and Therapy
Vol. 7 No. 3 (2011)
https://doi.org/10.4081/ecj.2011.3.9

The use of the biomarker “copeptin” for the diagnosis of acute chest pain in the Emergency Department

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: 9 January 2013
Published: 9 September 2011
1086
Views
1839
Downloads
copeptin, biomarkers, chest pain, emergency room

Authors

Elisa Conti
lucia.zoppi@pagepress.org
Emergency Department, University Hospital of Bologna - S. Orsola-Malpighi, Italy.
Marcello Guidi
Emergency Department, University Hospital of Bologna - S. Orsola-Malpighi, Italy.
Cavazza Mario
Emergency Department, University Hospital of Bologna - S. Orsola-Malpighi, Italy.
The aim of the study is to assess if copeptin, in combination with negative troponin, is able to accelerate the rule-out of AMI in patients with chest pain. The study was retrospectively conducted on three groups of patients selected according to their discharge diagnoses: patients with non-ST elevation myocardial infarction (NSTEMI), non-cardiac chest pain (NCCP), unstable angina (UA). Comparing the levels of copeptin, we found that the diagnosis of AMI is associated more often with copeptin positive values (> 14 pmol/l) than the diagnosis of NCCP and UA. However, about a quarter of our patients in which the combination of copeptin and troponin in the first blood sample was negative, the final diagnosis was AMI. According to our results, the combination of the two negative markers does not allow a safe rule out of AMI at time zero.

Downloads

Download data is not yet available.

How to Cite



The use of the biomarker “copeptin” for the diagnosis of acute chest pain in the Emergency Department. (2011). Emergency Care Journal, 7(3), 9-12. https://doi.org/10.4081/ecj.2011.3.9

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.